Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection
Status:
Not yet recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy of dual therapy compared with bismuth-containing
quadruple therapy as first-line treatment for Helicobacter Pylori eradication, as well as the
safety and economic benefits.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University